Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will participate in the Jefferies Global Healthcare Conference in New York from June 2-4, 2026. CEO Sergio Traversa and CFO Maged Shenouda will join a fireside chat on Thursday, June 4, 2026, at 12:50 PM ET.
A live webcast and 90-day replay will be available via the Relmada investor relations website, and management will hold one-on-one investor meetings scheduled through Jefferies.
Positive
- None.
Negative
- None.
News Market Reaction – RLMD
In the May 28 session, RLMD declined 0.14%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Earnings and update | Positive | +0.5% | Q1 2026 results, strong NDV‑01 data, funding runway projected through 2029. |
| May 06 | Earnings date set | Neutral | +6.9% | Announcement of timing for Q1 2026 results call and webcast. |
| May 05 | Conference abstracts | Positive | -0.8% | Plan to present NDV‑01 Phase 2 update and Phase 3 overview at AUA2026. |
| Mar 19 | Earnings and financing | Positive | -2.9% | Strong NDV‑01 data plus completion of $160M PIPE financing. |
| Mar 12 | Earnings date set | Neutral | -2.7% | Scheduling of Q4 2025 results call and webcast details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates (NDV-01 data, financing strength) often saw muted or even negative next-day price moves, with only one of the last five news events showing clearly aligned positive follow‑through.
Over the last few months, Relmada has focused investor attention on NDV‑01 and sepranolone. On Mar 19, it reported strong Phase 2 NDV‑01 data and a $160M PIPE financing. Subsequent Q1 2026 results on May 12 highlighted high complete response rates in high‑risk NMIBC and cash projected to fund operations through 2029. Multiple earnings‑date notices and the AUA2026 presentation update framed a steady cadence of communications. Today’s conference appearance fits this ongoing investor‑relations outreach rather than a new clinical or financial inflection point.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.
Jefferies Global Healthcare Conference Details
Format: Fireside Chat
Date: Thursday, June 4, 2026
Time: 12:50 PM ET
Webcast: Click Here
Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.
The webcast can also be accessed on the Events page of the Investors section of the Relmada website at https://www.relmada.com/for-investors/ir-calendar. An archived replay will be available for 90 days following the conclusion of the event.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
